J&J reveals just how much economic turbulence is affecting Big Pharma

The healthcare giant showed pharmaceutical gains, but that's no thanks to the economic environment of persistent inflation and a strong U.S. dollar.

By Michael Gibney • Oct. 20, 2022

Woman of the Week: Exscientia’s Charlotte Deane

Is the industry ready for a biologic discovery revolution? Charlotte Deane, chief scientist of biologics AI at Exscientia, thinks so.

By Taren Grom • Oct. 19, 2022

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

He helped discover BMS’s psoriasis pill Sotyktu. Here’s what he has to say about early science in Big Pharma

Bristol Myers Squibb’s senior principal scientist Ryan Moslin shares why his team was built for success and how they ushered a potential psoriasis blockbuster through discovery.

By Michael Gibney • Oct. 17, 2022

BIO’s interim CEO and Alvotech’s new chief quality officer could spell big changes for biotech

What these life science organizations’ latest executive-level appointments mean for the industry.

By Karissa Waddick • Oct. 14, 2022

What’s your leadership brand?

Pharma industry leaders share their brand personas.

By Taren Grom • Oct. 14, 2022

Coming out of stealth, RIGImmune aims to catch up with ever-mutating viruses

President Susan Sobolov discusses how the startup is building on the work of two powerhouse Yale scientists to advance candidates for viruses — and beyond.

By Kelly Bilodeau • Oct. 13, 2022

Where the CEO of ADC Therapeutics sees ‘huge potential’ in the tech beyond oncology

The “magic bullet” approach of ADCs has been a breakthrough in cancer care — but this excitement could be just the beginning.

By Meagan Parrish • Oct. 12, 2022

Woman of the Week: HBA’s Nikki Jones

As the Healthcare Businesswomen’s Association’s first chief people and DEI officer, Jones is poised to tackle pay gap inequity, systemic gender bias and leadership barriers impeding women of color.

By Taren Grom • Oct. 12, 2022

Are you a bad boss?

Pharma execs share their tips for being a better leader.

By Taren Grom • Oct. 7, 2022

Woman of the Week: Janssen’s Fiona Elwood

The neurodegeneration lead at Janssen is driving precision-based medicine to better understand the pathology of neurological disease for the greatest patient impact.

By Taren Grom • Oct. 5, 2022

The 2 areas in life sciences most in need of talent

The industry is feeling the hiring crunch — here’s what pharma companies can do to mitigate the impact.

By Meagan Parrish • Oct. 4, 2022

Keytruda is the gift that keeps on giving for Merck, and here’s what’s next for the cancer juggernaut

Long-term results showed five-year survival numbers for lung cancer patients that surpassed all others, and Merck's VP of oncology research tells us what he's excited about.

By Michael Gibney • Oct. 3, 2022

How do Biogen-Eisai’s two Alzheimer’s drugs stack up?

Biogen and Eisai's newest Alzheimer's success begs comparison to their past debacle — and bolsters the amyloid theory.

By Michael Gibney • Sept. 30, 2022

Woman of the Week: Pepper Bio’s Samantha Dale Strasser

The co-founder of Pepper Bio entered the biotech world three years ago with the goal of transforming drug discovery through the emerging discipline of transomics.

By Taren Grom • Sept. 28, 2022

Woman of the Week: Agilent Technologies’ Dr. Katharine Knobil

As the first chief medical officer of the diagnostic testing company, Dr. Katharine Knobil is focused on moving the science forward beyond precision oncology to liquid biopsy.

By Taren Grom • Sept. 14, 2022

From the ‘go-go days’ to a bubble crunch — the biotech sector faces its next challenge

The highs of the sector in early 2021 gave way to a bear market that persisted into the second half of this year — but there's hope the bubble hasn't popped for good.

By Michael Gibney • Sept. 12, 2022

Woman of the Week: Foresite Capital’s Cindy Mesaros

The longtime marketing pro details her fascinating career journey and how she’s positioning early stage health companies to thrive. 

By Taren Grom • Sept. 7, 2022

First 90 Days: Adaptive Biotech’s Tycho Peterson

A long-time analyst, Tycho Peterson brings his business savvy to the C-suite at Adaptive, where he began as CFO in June with a knowledge of what works and what doesn't in the diagnostics space.

By Michael Gibney • Sept. 1, 2022

Woman of the Week: Thread’s Kim Boericke

Fresh off an eight-year tour of duty at ICON, the CRO industry veteran is stepping into a new role and a new title as chief delivery officer at Thread.

By Taren Grom • Aug. 31, 2022

Leading the industry’s next potential game-changer in drug discovery

Rachel Meyers, chief scientific officer at Faze Medicines, is helping guide the company towards the development of biomolecular condensates — an emerging field that could transform drug discovery.

By Alexandra Pecci • Aug. 29, 2022

Woman of the Week: Glympse Bio’s Dr. Tram Tran

How the chief medical officer of the emerging diagnostic company is using the patient perspective as a guiding light.

By Taren Grom • Aug. 24, 2022

Moderna, Eli Lilly and Schrödinger seek to boost financial and people strategies with key new hires

How the latest personnel shifts are impacting each company and the industry at large. 

By Karissa Waddick • Aug. 24, 2022

The story behind the PharmaVoice 100

Taren Grom, our founding editor and the feature’s originator, explains how the coveted PharmaVoice 100 awards got its start and what makes it stand out in the industry.

By Meagan Parrish • Aug. 23, 2022

As pharma M&A ramps up, U.S. execs are bullish on more deals

What top executives at Merck, Pfizer and more are saying about M&A as they move into the second half of the year.

By Michael Gibney • Aug. 11, 2022

Woman of the Week: COTA’s Miruna Sasu

Miruna Sasu is on a mission to use real world data to help wipe out cancer. She believes this audacious goal is within reach, and as president and CEO of COTA, she is inspiring her team to create a “path to care” for oncology patients.

By Taren Grom • Aug. 10, 2022